Press Releases Palatin Technologies, Inc.

Equities

PTN

US6960775020

Delayed Nyse Other stock markets 03:56:37 2024-04-29 pm EDT			5-day change	1st Jan Change
1.78 ^USD	-2.20%		+2.91%	-55.53%

Apr. 08	Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	CI
Feb. 28	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024	Apr. 09	AQ
PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	Feb. 29	AQ
PALATIN ANNOUNCES DATABASE LOCK FOR PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	Feb. 06	AQ
PALATIN ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING	Jan. 31	AQ
PALATIN PROVIDES CORPORATE UPDATE AND HIGHLIGHTS STRATEGIC PRIORITIES FOR CALENDAR YEAR 2024	Jan. 09	AQ
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.	Jan. 03	BU
PALATIN REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	Nov. 15	AQ
PALATIN TO REPORT FIRST QUARTER FISCAL YEAR 2024 RESULTS, TELECONFERENCE AND WEBCAST TO BE HELD ON NOVEMBER 14, 2023	Nov. 10	AQ
PALATIN ANNOUNCES CLOSING OF $5 MILLION REGISTERED DIRECT OFFERING	23-10-25	AQ
PALATIN ANNOUNCES POSITIVE PRECLINICAL DATA SHOWING SYNERGISTIC WEIGHT LOSS, INITIATING CLINICAL STUDY OF MELANOCORTIN 4 RECEPTOR AGONIST + GLP-1 IN OBESE PATIENTS	23-10-19	AQ
PALATIN PRESENTS DATA AT THE UNITED EUROPEAN GASTROENTEROLOGY WEEK 2023 CONFERENCE ON PL8177 ULCERATIVE COLITIS TREATMENT	23-10-17	AQ
PALATIN RECEIVES NOTICE OF NON-COMPLIANCE FROM NYSE AMERICAN	23-10-16	AQ
PALATIN REPORTS FOURTH QUARTER AND FISCAL YEAR ENDED 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	23-09-29	AQ
PALATIN TO REPORT FOURTH QUARTER AND FISCAL YEAR END 2023 RESULTS, TELECONFERENCE AND WEBCAST TO BE HELD ON SEPTEMBER 28, 2023	23-09-25	AQ
PALATIN INITIATES CLINICAL PROGRAM FOR BREMELANOTIDE CO-FORMULATED WITH A PDE5I FOR THE TREATMENT OF ED IN PATIENTS NON-RESPONSIVE TO PDE5I TREATMENT	23-08-11	AQ
PALATIN'S VYLEESI LICENSEE FOSUN PHARMA REPORTS FIRST COMMERCIAL SALE IN CHINA AND SOUTH KOREAN LICENSEE KWANGDONG PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 CLINICAL STUDY	23-08-09	AQ
PALATIN ANNOUNCES DIRECT-TO-CONSUMER TELEHEALTH PARTNERSHIP WITH UPSCRIPTHEALTH FOR VYLEESI	23-08-08	AQ
PALATIN TO PARTICIPATE IN CANACCORD GENUITY'S 43RD ANNUAL GROWTH CONFERENCE	23-08-07	AQ
PALATIN ANNOUNCES PRELIMINARY FOURTH QUARTER FISCAL 2023 VYLEESI PRODUCT REVENUE RESULTS	23-07-12	AQ
PALATIN PRESENTS PRECLINICAL DIABETIC NEPHROPATHY DATA AT THE INTERNATIONAL PODOCYTE CONFERENCE	23-05-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Palatin Technologies, Inc.

Equities

PTN

US6960775020

Press Releases

Filters